Literature DB >> 1603892

Early dyskinesia--vulnerability.

J O Cole1, G Gardos, L A Boling, D Marby, D Haskell, P Moore.   

Abstract

Relative vulnerability to dyskinesia in terms of exposure to antipsychotic drugs prior to onset of dyskinesia was studied in a sample of 100 psychiatric patients with dyskinesia onset generally within a year or less of the point of study entry. Unipolar and bipolar patients were more vulnerable to dyskinesia than other diagnostic groups. In the total sample, lithium exposure did not appear to delay development of dyskinesia. Longer exposure to antiparkinson drugs was associated with delayed onset of dyskinesia. Past exposure to electroconvulsive therapy was related to decreased vulnerability to dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603892     DOI: 10.1007/bf02245263

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  Tardive dyskinesia and psychotropic drug history.

Authors:  G M Simpson; E Varga; J H Lee; B Zoubok
Journal:  Psychopharmacology (Berl)       Date:  1978-07-06       Impact factor: 4.530

2.  Research diagnoses for tardive dyskinesia.

Authors:  N R Schooler; J M Kane
Journal:  Arch Gen Psychiatry       Date:  1982-04

3.  The effect of lithium on an animal model of tardive dyskinesia.

Authors:  H L Klawans; W J Weiner; P A Nausieda
Journal:  Prog Neuropsychopharmacol       Date:  1977

4.  Integrating incidence and prevalence of tardive dyskinesia.

Authors:  J M Kane; M Woerner; M Borenstein; J Wegner; J Lieberman
Journal:  Psychopharmacol Bull       Date:  1986

Review 5.  Tardive dyskinesia and anticholinergic drugs.

Authors:  G Gardos; J O Cole
Journal:  Am J Psychiatry       Date:  1983-02       Impact factor: 18.112

6.  A prospective study of tardive dyskinesia development: preliminary results.

Authors:  J M Kane; M Woerner; P Weinhold; J Wegner; B Kinon
Journal:  J Clin Psychopharmacol       Date:  1982-10       Impact factor: 3.153

Review 7.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

8.  Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.

Authors:  G Gardos; J O Cole; R M Rapkin; R A LaBrie; E Baquelod; P Moore; R Sovner; J Doyle
Journal:  Arch Gen Psychiatry       Date:  1984-11

9.  Prevalence of tardive dyskinesia in affective disorder patients.

Authors:  R Yassa; A M Ghadirian; G Schwartz
Journal:  J Clin Psychiatry       Date:  1983-11       Impact factor: 4.384

10.  Tardive dyskinesia in the aged. Duration of treatment relationships.

Authors:  L M Toenniessen; D E Casey; B H McFarland
Journal:  Arch Gen Psychiatry       Date:  1985-03
View more
  3 in total

Review 1.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 2.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

3.  The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.

Authors:  Daniel M Blumberger; Benoit H Mulsant; Dora Kanellopoulos; Ellen M Whyte; Anthony J Rothschild; Alastair J Flint; Barnett S Meyers
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.